PHP18 IMPACT OF STEPS (SAFE, THERAPEUTIC AND ECONOMIC PHARMACEUTICAL SELECTION) MODEL ON PRESCRIBING COSTS OF STATINS  by Alabbadi, I et al.
A149Abstracts
OBJECTIVES: Donabedian described client satisfaction as “the
ultimate validator” of quality in health care. Identify items in the
Medicare Current Beneﬁciary Survey (MCBS)—-2002 as mea-
sured by satisfaction regarding health care access that correlate
with satisfaction with quality of care. This is the ﬁrst step in
developing a new model that relates health care access to health
care quality as measured by consumer/patient satisfaction.
METHODS: Access items from the survey were measured by a
4-point satisfaction scale: 1 = very satisﬁed to 4 = very dissatis-
ﬁed. Only responses on the 1 to 4 scale were used; all other
responses or non-responses were considered as missing data. The
missing data then were imputed employing the EM algorithm;
complete cases were used in the analysis (N = 16,087). A linear
regression model by weighted least squares using the one-year
cross-sectional weights from the MCBS is done using items in
the survey, measured by satisfaction, that correspond to Pen-
chansky and Thomas’ ﬁve dimensions of health care access-
accessibility, acceptability, accommodation, affordability, and
availability- and are regressed on the dependent variable
MCQUALTY (satisfaction with medical care received in last
year). RESULTS: The regression model identiﬁed sixteen of 20
eligible items that signiﬁcantly correlated (p < 0.05) to satisfac-
tion with quality of care in the Medicare population of 2002.
CONCLUSIONS: Health care access and quality of care as mea-
sured by satisfaction have signiﬁcant correlation in the Medicare
population.
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The Saudi Arabian Ministry of Health (MOH) controls the uti-
lization of the free pharmacy beneﬁt program (PBP) by having a
closed universal formulary and ensures the effectiveness of the
PBP by instituting a pharmacy & therapeutics (P&T) committee
in each hospital. OBJECTIVES: To test the relationship among
the levels of development P&T committees and patients’ access
rates to prescription drugs. METHODS: A cross-sectional
descriptive survey design was conducted in the ﬁrst phase and
covered 127 MOH pharmacy managers at non-specialized hos-
pitals. The survey gathered information about: hospital, phar-
macy, and P&T committee characteristics. The survey results
were used to classify the MOH hospitals according to the levels
of development of the P&T committee. In the second phase, the
prescription audit phase, hospitals deliberately were selected
based on the hospitals’ P&T committee levels of development.
From each hospital, 150 patient records were systematically
sampled and patient’s access rate was calculated for each patient.
Analysis of variance (ANOVA) was used to test the existence of
a signiﬁcant difference in the access rates across the levels of
development of P&T committee. RESULTS: Of 127 MOH hos-
pitals, 81 (63.7%) hospitals were valid for the analysis. Of 81
hospitals, 13, 24, 39, 5 hospitals have undeveloped, poorly, par-
tially, and developed P&T committees, respectively. A total of
6885 prescription drugs were prescribed for 2850 patients in 19
audited hospitals. The overall rate for patients’ access was
97.3%. The ANOVA tests for the existence of a signiﬁcant dif-
ference of access rates across the levels of development of P&T
committee showed mixed results. CONCLUSIONS: The positive
relationship between the levels of development of P&T commit-
tee and patient’s access to prescription drugs was not conclusive.
However, the ﬁnding might be due to lack of enough data and
controls of other confounding variables rather than inexistence
of the relationship.
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OBJECTIVES: A newly developed 90-day retail-dispensing
program allows members to obtain 90-day supplies of mainte-
nance medications through a retail pharmacy stores at a discount
co-payment. The objective of this study is to investigate if there
is any relationship between generic utilization observed in pre-
scriptions dispensed through this channel and members’ co-pay
difference between brand and generic medications. METHODS:
The analysis was conducted using pharmacy claim data obtained
from a pharmacy beneﬁt management organization. Clients
included in the analysis were those who implemented the 90-day
retail program from January 2004 to July 2004 and also allowed
its members to obtain prescriptions through both 90-day mail
and 30-day retail channels. The relationship between generic uti-
lization and co-pay structure was assessed using multiple regres-
sion analysis. The dependent variable was proportion of generic
prescription claims dispensed through 90-day retail channel. The
independent variables were ratio of brand to generic cost, the
absolute co-pay amount difference between brand and generic
medications, age, gender, and prior generic utilization of 90-day
mail as well as 30-day retail program. RESULTS: A total of 25
clients were included in the analysis. In 90-day retail program,
the generic utilization ranged from 21.5% to 77.5%, ratio of
brand to generic cost varied from 1.9 to 6.2, and absolute co-
pay amount difference between brand and generic medications
varied from $11.2 to $101.5. A linear, positive relationship was
observed between generic utilization and ratio of brand to
generic cost (P < 0.05). Previous 90-day mail generic utilization
was also found to have positive impact on the 90-day retail
generic utilization (P < 0.05). CONCLUSIONS: Study results
indicate an increase in co-pay difference between brand and
generic medications do have a positive impact on 90-day retail
generic utilization. Further investigation is needed to test the
relationship between co-pay structure and generic utilization
among different channels.
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OBJECTIVE: STEPS is a structured model for the selection of
drugs for formulary inclusion. The aim of this study was to use
the STEPS model in the selection of statin products for use within
a health board in Northern Ireland. METHODS: The STEPS
model involved three phases in sequence: an evidence based
pharmacotherapeutic evaluation of all available statin drug enti-
ties in the UK, a separate safety/risk assessment analysis of
product lines of drug entities which exceeded the pharma-
cotherapeutic threshold and ﬁnally a budget impact analysis. A
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comprehensive literature review, with expert panel judgment,
informed the selection of criteria (and their relative weighting)
for the pharmacotherapeutic evaluation. The resultant scoring
system was circulated (in questionnaire format) to prescribers
and stakeholders for comment. Based on statistical analysis of
the latter survey results, the ﬁnal scoring system was developed.
Drug entities which exceeded the evidence threshold score were
entered into a tendering process with pharmaceutical suppliers.
Product lines submitted as a result of the tendering process were
sequentially entered into the second and third phases of the
STEPS process (safety/risk assessment; budget impact analysis).
RESULTS: Three drug entities (from the 5 currently available in
the UK) exceeded the evidence threshold and 29 from 39 sub-
mitted product lines, containing these drug entities, satisﬁed the
safety evaluation/risk assessment criteria. Two product lines,
each containing a different drug entity, were selected for formu-
lary inclusion as a result of the budget impact analysis. The esti-
mated annual cost savings for statins as a result of this selection
process (based on estimated annual usage in Deﬁned Daily
Doses) in this health board, was 40%. CONCLUSION: The
STEPS model has a signiﬁcant contribution to make in contain-
ing statin costs while retaining the most therapeutically appro-
priate agents.
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OBJECTIVES: The purpose of the study is to evaluate the impact
of a tablet splitting program in a large pharmacy beneﬁt man-
agement organization on the costs and utilization of prescription
drugs. METHODS: Using a retrospective cohort study design,
prescription records from January 1, 2005 to June 30, 2005 were
obtained from a pharmacy claims database. Three study cohorts-
voluntary, mandatory, and control cohort were created based on
the enrollment status in the tablet splitting program. The number
of prescriptions dispensed, the total costs and savings per pre-
scription were analyzed and compared for the study drugs
Lexapro, Lipitor, and Zoloft. RESULTS: A total of 606,068 pre-
scriptions, 594,825 in the control, 5226 in the mandatory and
6017 in the voluntary cohort were included. Total cost savings
were obtained by subtracting the difference in cost/days supply
between drugs in the control group and each active treatment
group. Total cost savings are at $179,575.85 and $74,119.53 for
the mandatory and the voluntary cohort respectively after adjust-
ing for the operation costs and subtracting the costs from the
treatment cohorts. An average per prescription cost saving of
$34.36 for the mandatory and $12.31 for the voluntary program
was realized for the three drugs studied. CONCLUSIONS: A
tablet splitting program has been shown to produce signiﬁcant
savings, $34.36 and $12.31 per prescription for the health plan
enrolled in the mandatory and voluntary programs respectively.
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OBJECTIVES: The purpose of this study was to perform a lon-
gitudinal content analysis to assess trends in contributed research
papers presented at ISPOR Annual Meetings and European Con-
gresses from 1998 through 2005 as available in the ISPOR
Research Digest at www.ispor.org, as well as to assess research
quality indicators. METHODS: The database of 5852 con-
tributed presentations at the ISPOR meetings from 1998 through
2005 were analyzed for trends and quality indicators. Trends
were evaluated for outcomes assessed (clinical, economic,
patient-reported outcomes), and types of health policy and dis-
eases studied. Quality indicators were deﬁned as abstracts
including “study perspective, “discounting”, or “ statistical con-
siderations (“conﬁdence interval”, “standard deviation”,
“mean/median”, “sensitivity analysis”). RESULTS: ISPOR held
16 international meetings during 1998–2005. The annual
number of contributed research presentations increased from
270 to 1248 for an eight-year total of 5852 with all topics and
disease categories increasing over time. The major topic areas
covered were cost (42%), patient-reported outcomes including
methods (23%), health policy (23%), methods and concepts
(10%), and clinical outcomes evaluations (6.4%). The top 
four diseases (4992 disease-speciﬁed papers) were neurologi-
cal/mental health (18.5%), cardiovascular (17%), cancer (9%),
and infectious diseases (10%). With respect to quality indicators,
of the abstracts analyzed, a study perspective was mentioned in
18% (37% cost studies, & all others ~4% each); discounting in
8% (16% cost studies & all others <2% each). For statistical
considerations, the percent mentioning mean, median, standard-
deviation, conﬁdence intervals, or sensitivity analysis (12%), was
41%. Overall, the percent of abstracts with these quality indi-
cators generally increased over the study period. CONCLU-
SION: The number of papers has increased over the study period
for multiple topics and diseases. Although the general quality of
papers, as considered in this analysis, was increasing, the percent
of papers that include these quality indicators needs further eval-
uation & improvement.
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OBJECTIVE: The aim of the study to calculate the Lorenz con-
centration curves and Gini coefﬁcient of health expenditures in
Hungary. METHODS: Data derived from the ﬁnancial database
of the Hungarian National Health Insurance Fund Administra-
tion, covering the period 2000–2004. The Hungarian health care
ﬁnancing system based on a regular patient level data reporting
system which allows us to calculate the cumulative frequency dis-
tributions of health expenditures. In each type of care we put the
patients into 100 percentile group ranked by the health expen-
ditures. RESULTS: The top quadrant (top 25%) of the patients
(with highest health expenditures) received different portion of
health expenditures (2004): 72.4% in out-patient care, 64.1%
in in-patient care, 67.3% in chronic care, 56.3% in CT/MRI
examinations, 56.2% in home care, 46.1% in renal dialysis,
83.8% in drug reimbursement, 83.6% in medical devices reim-
bursement. The visual Lorenz curves are presented for each type
of care mentioned earlier and for the ﬁve years between
20000–2004. There was not any signiﬁcant time trend within the
same type of care. We found the following Gini coefﬁcients
(2004): out-patient care: 0.6352, in-patient care: 0.5278, chronic
care: 0.5624, CT/MRI examinations: 0.4459, home care:
0.4319, renal dialysis: 0.4251, drug reimbursement: 0.7444,
medical devices reimbursement: 0.7480. We found signiﬁcant
